Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases.

MLA

Bandeira, Matilde, et al. “Off-Label Use of Mycophenolate Mofetil in the Treatment of Rare and Complex Rheumatic Connective Tissue Diseases.” Clinical and Experimental Rheumatology, vol. 40 Suppl 134, no. 5, May 2022, pp. 32–39. EBSCOhost, https://doi.org/10.55563/clinexprheumatol/v1e7s2.

APA

Bandeira, M., Vieira, A., Guimarães, V., Bento, T., Amoura, Z., Arnaud, L., Beretta, L., Cere, A., Chehab, G., Hachulla, E., Milas-Ahić, J., Müller-Ladner, U., Nagy, G., Piette, Y., Rednic, S., Schneider, M., Smith, V., Cutolo, M., Fonseca, J. E., & Romão, V. C. (2022). Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases. Clinical and Experimental Rheumatology, 40 Suppl 134(5), 32–39. https://doi.org/10.55563/clinexprheumatol/v1e7s2

Chicago

Bandeira, Matilde, Ana Vieira, Vera Guimarães, Tatiana Bento, Zahir Amoura, Laurent Arnaud, Lorenzo Beretta, et al. 2022. “Off-Label Use of Mycophenolate Mofetil in the Treatment of Rare and Complex Rheumatic Connective Tissue Diseases.” Clinical and Experimental Rheumatology 40 Suppl 134 (5): 32–39. doi:10.55563/clinexprheumatol/v1e7s2.